The overall goal of the Clinical Core is to generate data and biospecimens required to support high quality, cutting edge, externally-funded clinical and clinical-pathologic studies that focus on the full spectrum of cognition from normal aging to mild cognitive impairment (MCI) to the earliest stages of dementia among older African Americans. Historically, progress in Alzheimer's disease (AD) research has been most striking among members of the U.S. non-Hispanic white population. However, because of the expected increase in the growth of the older African American population, because African Americans may be at greater risk of AD than whites, and the burden of AD and mixed dementias is projected to increase dramatically for this population, the Rush Clinical Core will focus on enrolling and following African Americans longitudinally to accomplish the following Specific Aims: 1) Continue to recruit and enroll African Americans without dementia who agree to annual, detailed clinical evaluations and collection of ante-mortem biologic specimens;2) Continue to conduct uniform structured baseline and annual follow-up evaluations, including neurological examination and neuropsychological performance testing, of community-dwelling Clincal Core participants, apply uniform diagnostic criteria for incident AD, MCI, and mixed dementias as specified in the UDS, and supplement UDS data collection with an extended battery of tests to increase compatibility with the Religious Orders Studies Core;3) Integrate innovative and culturally tailored educational programs into the clinical evaluation to increase awareness of the importance of brain autopsy in African Americans and to facilitate a high autopsy rate with a short post-mortem interval;and continue to harvest and preserve the brain tissue in a fashion that retains maximum flexibility to support a diverse array of studies;and 4) Increase capacity to conduct externally funded clinical, neuropsychological, and clinical-pathological research studies, including studies that incorporate contemporary biochemical and molecular techniques, by contributing data to NACC and providing an environment and resources to facilitate entry of subjects, clinical data, and post-mortem tissue into research projects at Rush and within the AD research community at large.
The Rush Clinical Core will generate data and biospecimens to support high quality, cutting edge clinical and clinical-pathologic studies that focus on the full spectrum of cognition in older African Americans, one of the fastest growing populations in the U.S. Knowledge gained through studies supported by the Core will advance our understanding of the clinical and neuropathoiogic transitions from normal cognition to dementia.
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8|
|Forrester, Sarah N; Gallo, Joseph J; Smith, Gwenn S et al. (2016) Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia. Am J Geriatr Psychiatry 24:117-25|
|Wilson, Robert S; Rajan, Kumar B; Barnes, Lisa L et al. (2016) Factors related to racial differences in late-life level of cognitive function. Neuropsychology 30:517-24|
|Ibrahim-Verbaas, C A; Bressler, J; Debette, S et al. (2016) GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Mol Psychiatry 21:189-97|
|John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the Î´ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960|
|Mufson, Elliott J; Malek-Ahmadi, Michael; Snyder, Noelle et al. (2016) Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiol Aging 43:101-10|
|Montine, Thomas J; Monsell, Sarah E; Beach, Thomas G et al. (2016) Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimers Dement 12:164-9|
|Lim, Andrew S P; Bennett, David A; Buchman, Aron S (2016) Response to Letter Regarding Article, ""Sleep Fragmentation, Cerebral Arteriolosclerosis, and Brain Infarct Pathology in Community-Dwelling Older People"". Stroke 47:e175|
|Liu, Rui-Xuan; Huang, Cui; Bennett, David A et al. (2016) The characteristics of astrocyte on AÎ² clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res 8:4082-4094|
|Dodge, Hiroko H; Zhu, Jian; Woltjer, Randy et al. (2016) Risk of incident clinical diagnosis of Alzheimer's disease-type dementiaÂ attributable to pathology-confirmed vascular disease. Alzheimers Dement :|
Showing the most recent 10 out of 586 publications